JP2009502914A5 - - Google Patents

Download PDF

Info

Publication number
JP2009502914A5
JP2009502914A5 JP2008523847A JP2008523847A JP2009502914A5 JP 2009502914 A5 JP2009502914 A5 JP 2009502914A5 JP 2008523847 A JP2008523847 A JP 2008523847A JP 2008523847 A JP2008523847 A JP 2008523847A JP 2009502914 A5 JP2009502914 A5 JP 2009502914A5
Authority
JP
Japan
Prior art keywords
disorders
withdrawal
substance
withdrawal symptoms
induced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008523847A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009502914A (ja
JP5094720B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/026439 external-priority patent/WO2007018496A1/en
Publication of JP2009502914A publication Critical patent/JP2009502914A/ja
Publication of JP2009502914A5 publication Critical patent/JP2009502914A5/ja
Application granted granted Critical
Publication of JP5094720B2 publication Critical patent/JP5094720B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2008523847A 2005-07-26 2005-07-26 サブスタンス関連障害を処置する方法 Expired - Fee Related JP5094720B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2005/026439 WO2007018496A1 (en) 2005-07-26 2005-07-26 Methods for treating substance-related disorders

Publications (3)

Publication Number Publication Date
JP2009502914A JP2009502914A (ja) 2009-01-29
JP2009502914A5 true JP2009502914A5 (cg-RX-API-DMAC7.html) 2012-03-29
JP5094720B2 JP5094720B2 (ja) 2012-12-12

Family

ID=35064669

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008523847A Expired - Fee Related JP5094720B2 (ja) 2005-07-26 2005-07-26 サブスタンス関連障害を処置する方法

Country Status (13)

Country Link
EP (1) EP1928451B1 (cg-RX-API-DMAC7.html)
JP (1) JP5094720B2 (cg-RX-API-DMAC7.html)
KR (1) KR101199499B1 (cg-RX-API-DMAC7.html)
CN (1) CN101272776B (cg-RX-API-DMAC7.html)
AT (1) ATE538784T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005335241B9 (cg-RX-API-DMAC7.html)
BR (1) BRPI0520451A2 (cg-RX-API-DMAC7.html)
CA (1) CA2616721C (cg-RX-API-DMAC7.html)
EA (1) EA019935B1 (cg-RX-API-DMAC7.html)
ES (1) ES2385087T3 (cg-RX-API-DMAC7.html)
IL (1) IL189003A0 (cg-RX-API-DMAC7.html)
NO (1) NO20080877L (cg-RX-API-DMAC7.html)
WO (1) WO2007018496A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101335941B1 (ko) 2005-06-08 2013-12-04 에스케이바이오팜 주식회사 수면-각성 장애의 치료
MX2012000034A (es) 2009-06-22 2012-02-21 Sk Biopharmaceuticals Co Ltd Metodos para el tratamiento o la prevencion de la fatiga.
US8232315B2 (en) * 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
AU2010316172B2 (en) 2009-11-06 2015-11-12 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
EP2496228B1 (en) 2009-11-06 2014-01-15 SK Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
RU2019114940A (ru) 2013-03-13 2019-06-28 ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи Лечение катаплексии
US9226910B2 (en) 2013-07-18 2016-01-05 Jazz Pharmaceuticals International Iii Limited Treatment for obesity
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
BR112019025286A2 (pt) 2017-06-02 2020-06-23 Jazz Pharmaceuticals Ireland Limited Métodos e composições para tratamento de sonolência excessiva
CN114096314A (zh) 2019-06-27 2022-02-25 沼泽敏彦 痴呆症的治疗和预防药
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
KR100858232B1 (ko) * 2001-02-27 2008-09-12 오르토-맥네일 파마슈티칼, 인코퍼레이티드 카바메이트 화합물을 포함하는 거동 장애 예방 또는 치료용 약제학적 조성물
IL157589A0 (en) * 2001-02-27 2004-03-28 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing or treating bipolar disorder
PL365021A1 (en) * 2001-02-27 2004-12-27 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating psychotic disorders
PT1383489E (pt) * 2001-02-27 2007-06-21 Ortho Mcneil Pharm Inc Compostos carbamato para utilização na prevenção ou tratamento de distúrbios neurodegenerativos
US20070021500A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection

Similar Documents

Publication Publication Date Title
JP2009502914A5 (cg-RX-API-DMAC7.html)
Kumru et al. Rapid eye movement sleep behavior disorder in parkinsonism with parkin mutations
Murray et al. Insomnia caused by serotonin depletion is due to hypothermia
Mahowald et al. Parasomnias
Hassan et al. Novel psychoactive substances—recent progress on neuropharmacological mechanisms of action for selected drugs
JP2008534627A5 (cg-RX-API-DMAC7.html)
JP6421185B2 (ja) ベンゾイミダゾール−プロリン誘導体の使用
AU2021206771B2 (en) Cognitive disorder prevention and therapy
JP2017535612A5 (cg-RX-API-DMAC7.html)
JP2005523335A5 (cg-RX-API-DMAC7.html)
WO2008048410A3 (en) Diagnostic methods and genetic markers for alzheimer disease
Niaura et al. Varenicline
CN117500788A (zh) 作为血清素能药物的用于治疗与之相关的疾病的吲哚衍生物
Szily et al. Designer drugs in psychiatric practice-a review of the literature and the recent situation in Hungary
EA200601611A1 (ru) Терапия с применением производных 1-аминоциклогексана для лечения поведенческих нарушений, ассоциированных с болезнью альцгеймера
Manconi et al. Pramipexole versus ropinirole: polysomnographic acute effects in restless legs syndrome
Breuer et al. “Herbal seizures”–atypical symptoms after ibogaine intoxication: a case report
Bin et al. Preliminary evaluation of the efficacy and safety of brimonidine for general anesthesia
JP2008526706A5 (cg-RX-API-DMAC7.html)
JP2010505919A5 (cg-RX-API-DMAC7.html)
JP2006519251A5 (cg-RX-API-DMAC7.html)
CA2672920A1 (en) Aryl piperazine derivatives useful for the treatment of neuropsychiatric disorders
Patel et al. Effect of Alcohol on Brain Development
Khurshid et al. THE MULTIDIMENSIONAL EFFECTS OF METHAMPHETAMINE ON YOUTH IN PAKISTAN: A COMPREHENSIVE ANALYSIS
De la Herrán-Arita et al. Orexin/hypocretin antagonists in insomnia: From bench to clinic